These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15181744)

  • 21. Apolipoprotein E polymorphism and stroke in a population from eastern Turkey.
    Duzenli S; Pirim I; Gepdiremen A; Deniz O
    J Neurogenet; 2004; 18(1):365-75. PubMed ID: 15370197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apolipoprotein E polymorphism and dementia: a hospital-based study from southern India.
    Bharath S; Purushottam M; Mukherjee O; Bagepally BS; Prakash O; Kota L; Krishnappa SB; Sivakumar PT; Jain S; Varghese M
    Dement Geriatr Cogn Disord; 2010; 30(6):455-60. PubMed ID: 21252538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Association between estrogen receptor beta gene polymorphisms and Parkinson disease].
    Chen RJ; Zhang BS; Wang SM
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1185-8. PubMed ID: 18844113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study.
    Vefring H; Haugarvoll K; Tysnes OB; Larsen JP; Kurz MW;
    Acta Neurol Scand; 2010 Dec; 122(6):438-41. PubMed ID: 20456244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.
    Jellinger KA; Attems J
    Acta Neuropathol; 2008 Apr; 115(4):427-36. PubMed ID: 18273624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients.
    Bialecka M; Klodowska-Duda G; Kurzawski M; Slawek J; Gorzkowska A; Opala G; Bialecki P; Sagan L; Droździk M
    Parkinsonism Relat Disord; 2008 Dec; 14(8):636-40. PubMed ID: 18362084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein E polymorphism and clinical disease phenotypes in Arab patients with schizophrenia.
    Akanji AO; Ohaeri JU; Al-Shammri SN; Fatania HR
    Neuropsychobiology; 2009; 60(2):67-72. PubMed ID: 19752580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of hallucinations in Parkinson's disease using a novel scale.
    Wada-Isoe K; Ohta K; Imamura K; Kitayama M; Nomura T; Yasui K; Nakaso K; Nakashima K
    Acta Neurol Scand; 2008 Jan; 117(1):35-40. PubMed ID: 18095953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral changes associated with different apolipoprotein E genotypes in dementia.
    Cacabelos R; Rodríguez B; Carrera C; Beyer K; Lao JI; Sellers MA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S27-34. PubMed ID: 9339270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study.
    Kurz MW; Larsen JP; Kvaloy JT; Aarsland D
    Mov Disord; 2006 Dec; 21(12):2170-4. PubMed ID: 17029273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dementia in Thai patients with Parkinson's disease: analysis of 132 patients.
    Poungvarin N; Prayoonwiwat N; Devahastin V; Viriyavejakul A
    J Med Assoc Thai; 1996 May; 79(5):278-84. PubMed ID: 8708518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia.
    Gołab-Janowska M; Honczarenko K; Gawrońska-Szklarz B; Potemkowski A
    Neurol Neurochir Pol; 2007; 41(2):113-21. PubMed ID: 17530572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein E phenotype in demented patients in Greek population.
    Hatzifilippou E; Banaki T; Traka M; Koutsouraki E; Costa V; Baloyannis SJ
    Int J Neurosci; 2008 Jan; 118(1):163-72. PubMed ID: 18041613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in motor subtype and risk for incident dementia in Parkinson's disease.
    Alves G; Larsen JP; Emre M; Wentzel-Larsen T; Aarsland D
    Mov Disord; 2006 Aug; 21(8):1123-30. PubMed ID: 16637023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment.
    Kulisevsky J; Pagonabarraga J
    Mov Disord; 2009 Jun; 24(8):1103-10. PubMed ID: 19353727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
    Rabey JM; Prokhorov T; Miniovitz A; Dobronevsky E; Klein C
    Mov Disord; 2007 Feb; 22(3):313-8. PubMed ID: 17034006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
    Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
    Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study.
    Pedersen KF; Larsen JP; Alves G; Aarsland D
    Parkinsonism Relat Disord; 2009 May; 15(4):295-9. PubMed ID: 18801696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apolipoprotein E polymorphism in type 2 diabetic patients of Talca, Chile.
    Leiva E; Mujica V; Orrego R; Prieto M; Arredondo M
    Diabetes Res Clin Pract; 2005 Jun; 68(3):244-9. PubMed ID: 15936467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.